945MO AdvanTIG-206: Phase II randomized open-label study of ociperlimab (OCI) + tislelizumab (TIS) + BAT1706 (bevacizumab biosimilar) versus TIS + BAT1706 in patients (pts) with advanced hepatocellular carcinoma (HCC)

Zefang Ren, Yuhua Huang, Y B Guo, Ming‐Mo Hou, Wei Wang, Ming Kuang, Hao Chen, Wei Wang, Yaojun Zhang, Tianqiang Song, Chenyi Dai, K. Hsing-Tao, Victor Li, R. Abdrashitov, Lei Wang, Jun Fan